Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration
In July 2026, Repligen agreed to acquire BioLife Solutions in a deal worth $1.5bn. Repligen’s decision to buy a manufacturer …
Post
-
-
United global response to US childhood vaccine overhaul
International health authorities have launched a staunch defence of childhood immunisation, following a recent upheaval in the US that could …
-
Akeso secures China NMPA authorisation for ivonescimab combo
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination …
-
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits
Eli Lilly has initiated a crackdown to curb the trade of illicit forms of its investigational weight loss therapy, retatrutide, …
-
Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug …
-
Why your manufacturing floor is your greatest compliance risk – and opportunity
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to …
-
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
A patient who developed multidrug-resistant E. coli following a transplant has recovered following treatment with an investigational clustered regularly interspaced …
-
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs
Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the …
-
Epicrispr, Vaderis secure pivotal study funding for rare disease assets
Two biotech companies, Epicrispr Biotechnologies and Vaderis Therapeutics, have secured fresh capital to take their rare disease assets to late-stage …
-
Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial …
-
Alfasigma signs agreement to acquire Nordic Group
Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach …
-
Commercialising drugs in Europe: Lean models for first-time launchers
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% - …
-
Trump signs order that nearly halves childhood immunisation coverage
President Donald Trump has signed an executive order (EO) that significantly narrows the recommendations for paediatric immunisation, marking the latest …
-
Health tech’s role in obesity to expand beyond a ‘nice-to-have’
In recent years, there has been a sharp focus on treating obesity and its associated comorbidities, as the World Health …
-
UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Eli Lilly’s oral weight loss therapy, Foundayo (orforglipron), intensifying …
